Pre-Seed Funded Biotechnology Startups
The 50 most recent pre-seed rounds in biotechnology span June 2023 through July 2025, with the heaviest cluster of activity — 26 rounds — falling in 2024,…
The 50 most recent pre-seed rounds in biotechnology span June 2023 through July 2025, with the heaviest cluster of activity — 26 rounds — falling in 2024, and 2025 already showing 15 rounds through late July. Deal sizes vary dramatically at this stage: Sortera Bio in Cambridge raised $10M in June 2025, while DropGen in Basel and AgroGene Solutions in Ontario each closed at $30K. Roughly 11 of the 50 rounds carry undisclosed amounts, consistent with the opacity typical of earliest-stage biotech financing.
Geographic spread is notably broad. The United States contributes the largest share of companies, with entries across Massachusetts (100XBIO in Woburn, Envoya in Boston), New York, California, and smaller markets including Akron and Laramie. The United Kingdom fields five companies — three from London alone (Level Zero Health, Carbon Cell, Samphire Neuroscience) plus Sortera Bio in Cambridge and Fermtech in Oxford. Switzerland hosts four pre-seed biotech companies, including DropGen and NXI Therapeutics, both based in Basel.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed pre-seed rounds in this dataset?
Sortera Bio in Cambridge closed the largest disclosed round at $10M in June 2025, followed by Level Zero Health in London at $7M in February 2025. NXI Therapeutics in Basel raised $4M in June 2024, and Graph Therapeutics (Klosterneuburg), Pacifico Biolabs (Berlin), Psychae Therapeutics (Carlton), and Cascade Biocatalysts (Denver) each closed $3M rounds across 2023–2025.
Which cities and countries appear most often among these pre-seed biotech companies?
The United States has the largest share, spread across Boston, New York, San Diego, Denver, and smaller markets like Woburn and Akron. The United Kingdom fields five companies, with London alone hosting Level Zero Health, Carbon Cell, and Samphire Neuroscience, plus Sortera Bio in Cambridge and Fermtech in Oxford. Switzerland has four entries — DropGen and NXI Therapeutics both based in Basel — and Germany has three, split between Berlin and Darmstadt.
How many of these rounds have undisclosed amounts, and which companies are affected?
Eleven of the 50 rounds list no disclosed figure, including BioBlends (San Miguel de Tucumán), LigronBio (Newark, Delaware), Adoram Therapeutics (West Virginia), Cell Bauhaus (Melbourne), and MemoryCareAI (Newport Beach). Undisclosed rounds are distributed across the full date range, from MeCo Diagnostics in January 2024 to BioBlends in July 2025.
What is the realistic size range for disclosed pre-seed biotech rounds shown here?
Among the 39 rounds with disclosed amounts, the floor is $10K (Ubives, Budapest) and the ceiling is $10M (Sortera Bio, Cambridge). Most disclosed rounds fall between $100K and $3M; seven rounds closed at $2M or above, while ten rounds sit at $150K or below.
How does round activity break down by year across this dataset?
Nine rounds date to 2023 (the earliest being Solu in Helsinki, June 2023), 26 rounds closed in 2024, and 15 rounds have already been recorded in 2025 through July 23 — with bYoRNA in Bordeaux, BioBlends in Argentina, and DropGen in Basel among the most recent entries.
Are there non-traditional geographies represented in this pre-seed biotech segment?
Yes — the dataset includes companies from Romania (The Cat Health Company, Bucharest), Estonia (Gearbox Biosciences, Tartu), Hungary (Ubives, Budapest), Turkey (M-Based, Ankara), Argentina (BioBlends), and India (Human Biogenesis in Guwahati, Hummsa Biotech in Kolkata), indicating that pre-seed biotech financing is not confined to established life sciences corridors.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.